Royalty says it will pay $12.50 in cash for each share of Elan.
Research-based Pharmaceutical Industry Launches 'Do You Mind?' Campaign to Fight Mental and Neurological Disorders GENEVA , May 21, 2013 /PRNewswire...
Peregrine rises on agreement for late-stage study WASHINGTON (AP) — Shares of Peregrine Pharmaceuticals Inc. surged Monday after the company said it...
An interim analysis showed the drug wasn't helping patients live longer
Rise and shine, everyone. Another busy day is on the way, and we are no exception. We have an interesting meeting planned and, of course, various...
Another late sign-off as we tend to one of the short people. The homework is nearly done and we look forward to unwinding now. We hope you will have a chance to do the same. These items should help...
Altus Stock Falls On Revised Genentech Pact (Yahoo/Reuters)
Array, AstraZeneca Drug Fails Trial (Yahoo/AP)
Alzheimer's Institute Strikes Technology Deal With AstraZeneca (The Arizona Republic)
Astellas Low-Dose Drug Bests Rivals For Kidney Transplant Rejection (Yahoo/Reuters)
